Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron closed at $959.41 after a 4.73% gain, sitting 3.26% below its 52-week high of $991.73 and 92% of the way up its 52-week range. The stock has risen 25.77% over the past month and 42.23% over the past year, and it trades 28.80% above its 200-day average. The move follows a strong run of earnings: the October 30, 2026 report beat the EPS estimate by 23.51%, and the stock rose 13.33% in the first session afterward. The question now is whether a stock that has already rallied hard can keep its momentum while analysts' median target sits just above the price.

Regeneron reported adjusted EPS of $20.07 on October 30, 2026, against an analyst estimate of $16.25, a beat of 23.51%. The stock rose 13.33% in the first session after the report, the largest reaction in the seven-report record covered here. The beat was the third in a row of unusual size: the July 30, 2026 report beat by 39.96% and the stock rose 6.17%. The one beat that was followed by a lower price was the April 29, 2026 report, where EPS beat by 6.40% and the stock fell 6.21%. That pattern suggests the market has rewarded large surprises more reliably than small ones.

The stock trades at a trailing P/E of 21.21, which is 33.5% below the sector median of 31.9. On price-to-sales, however, it is more expensive: 6.39 against a sector median of 3.4, or 87.9% above. The gap between the two reflects strong margins. The net profit margin is 28.5% and the operating margin is 40.46%, and return on equity of 14.95% is above the sector median of 7.3%. Debt is light, with a debt-to-equity ratio of 0.08.

Of 28 analysts with a current rating, 19 rate the stock buy or strong buy, 9 rate it hold, and none rate it sell. Three months ago, 18 of 28 rated it buy. On November 2, 2026, six firms, including Leerink Partners, Bernstein, Morgan Stanley, Truist Securities, RBC Capital and Guggenheim, kept their ratings unchanged. The median 12-month target of $982.00 is only 2.3% above the price, so the consensus sees the shares as close to fair value after the rally.

Insiders sold $55.4 million of stock over the last 18 months across 22 sales, and made no open-market purchases. Insider sales are often planned in advance or made to cover tax on vesting shares, so they carry less weight than purchases would. Even so, the absence of insider buying is a fact investors weigh alongside a stock that has risen 42.23% in a year.

The base case is that the stock keeps trading above its moving averages while the business keeps growing faster than the sector. Revenue grew 16.73% in the latest quarter against a sector median of 8.1%, and analysts expect revenue to grow 22.7% this fiscal year. Analysts' EPS estimate for this year is $68.75, up 55.2%, but their estimate for next year is $62.12, a 9.6% decline, so much of the current earnings strength is expected to be a one-year step-up rather than a steady climb. The median 12-month analyst target is $982.00, only 2.4% above the price, which leaves little room for upside on the consensus view alone. A move above the 52-week high of $991.73 would put the stock at a new high and would likely need further earnings or pipeline news. A fall toward the 20-day EMA or the 50-day SMA would test whether the rally has support, and the lowest analyst target of $812.00 sits near the 50-day level. A simulation built from past volatility is not a forecast, but the stock's typical daily move of 3.03% gives a sense of how wide the swings can be.

Support sits first at the 20-day EMA of $875.37, the nearest level below the price. Below it, the 50-day SMA at $811.95 is the next support, and it also lines up with the lower end of analyst targets at $812.00. The 200-day SMA at $744.87 is the next level down, followed by the 52-week low of $591.52. Resistance is the 52-week high of $991.73, the nearest level above the price. A close above that high would be the first move into new territory, and the median analyst target of $982.00 sits just below it.